FDA legal instrument shows CV risk with etoricoxib and state of mind over lumiracoxib.

Feb 7, 2007 WA DC - An FDA memo shows that there are concerns over an element in cardiovascular risk with 2 new COX-2 selective inhibitors that are awaiting cognition in the US
This is a part of article FDA legal instrument shows CV risk with etoricoxib and state of mind over lumiracoxib. Taken from "Etoricoxib Arcoxia" Information Blog